SCHEMBL8117203

SCHEMBL8117203

CCN(CC)c1ccc(C(C(=O)NO)c2ccc(OC)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.49
ALDH1A1 P00352 3/20 0.49
TSHR P16473 1/20 0.49
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.48
GFER P55789 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CNR1 P21554 1/20 0.47
NPSR1 Q6W5P4 1/20 0.44
HDAC4 P56524 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4539123 0.87 TDP1 (0.51) CNR2ALDH1A1TSHRMAPTMAPK1
SCHEMBL2847510 0.84 HDAC4 (0.64) CNR2ALDH1A1TSHRMAPTGAA
SCHEMBL4524814 0.84 SLC2A1 (0.58) CNR2ALDH1A1MAPTGAASMN1; SMN2
SCHEMBL28785765 0.79 HDAC4 (0.70) CNR2ALDH1A1CNR1NPSR1HDAC4
SCHEMBL4541569 0.78 HDAC3 (0.51) CNR2ALDH1A1TSHRMAPTGAA
SCHEMBL20490337 0.77 HDAC4 (0.57) CNR2ALDH1A1TSHRMAPTGAA
SCHEMBL2847290 0.76 HDAC4 (0.68) CNR2ALDH1A1TSHRMAPTGAA
SCHEMBL1263095 0.76 ALDH1A1 (0.60) CNR2ALDH1A1TSHRMAPTGAA
SCHEMBL2839582 0.76 HDAC3 (0.55) CNR2ALDH1A1TSHRMAPTGAA
SCHEMBL2841700 0.75 HDAC3 (0.64) CNR2ALDH1A1CNR1NPSR1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP claimed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 CNR2 3937/4885ALDH1A1 532/4885TSHR 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.